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PREVENTION OF FIRST VARICEAL BLEEDING: NEW
PROSPECTS
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Saeed Hamid, Wasim Jafri ( Department of Medicine, The Aga Khan University Hospital, Stadium Road, Karachi. ) 
Propranolol lowers portal pressure although the exact mechanism of its action is uncertain. Initial
studies of the use of propranolol in cirrhotics were in the prevention of recurrent variceal hemorrhage.
However, results are very heterogenous and the use ofpropranolol in this situation remains
controversial. Results of trials of primary prophylaxis for variceal bleed are more encouraging and
recommendation can be made for the use of propranolol in patients with large varices who have never
bled. Practical problems with the use of beta blockers in portal hypertension are a variability of
response and the lack of clinical parameters to determine effectiveness.
BACKGROUND AND DEFINITIONS 
Pressure in the portal vein is normally between 5-10 mmHg which is only a few mmHg higher than in
the inferior vena cava. Vascular resistance to portal flow is thus very low. Portal hypertension is the
result of increased flow and increased resistance in the portal system and may be arbitrarily defined as
an increase in the resting portal pressure to above 12 mmHg1. Pharmacologic therapy is aimed at
altering these factors by the use of vasoconstrictors to reduce flow and vasodilators to reduce
resistance. Propranolol lowers portal pressure, measured directly2 or indirectly from the gradient
between wedged and free hepatic venous pressures (HVPG-HWVPFHVP) 3. The exact mechanism of
action of propranolol is uncertain but theoretically it may act by lowering cardiac output, by blocking
splanchnic arteriolar B2 receptors or by causing reflex stimulation of splanchnic arteriolar alpha-
adrenergic receptors, or combination of these, resulting in reduced splanchnic flow3,4. The extra-
cardiac mechanisms seem important as studies in cirrhotics suggest that selective B-blockers like
atenolol5 and metoprolol6 have less marked portal hemodynamic effects than propranolol. Azygous
blood flow, an indirect measure of collateral blood flow in cirrhotics that includes blood flowing
through esophageal varices, is reduced in every patient given propranolol7. In 1980, Lebrec et al8 first
proposed the use of oral propranolol as a means of reducing portal hypertension (PHT). Initial trials
since then concentrated on the use of propranolol for prevention of rebleeding from varices in cirrhotics
with PHT. However, recently attention has been focussed on primary prevention of variceal bleeding.
Review of literature on both these aspects and the difficulties with propranolol therapy are presented.
Propranolol for prevention of recurrent variceal bleeding
The pioneering work was reported by Lebrec et at9 on 74 patients, mostly alcoholic cirrhotics, who
were mainly in the Child’s category A. Oral propranolol was given twice daily to lower the resting
pulse rate by approximately 25%, the mean dose used being 159 ±83 mg. 87% patients in the treatment
group were free of rebleeding at 1 year vs 42% in the placebo group with the proportion being 79% vs
32% at two years. There was also a significant difference in survival in patients who had initially bled
from varices: 91% (propranolol) vs 53% (placebo). The enthusiasm generated by this study was how-
ever dampened by a negative study from Burroughs et al10. which showed no statistically significant
difference in rebleeding from varices - 46% (propranolol) vs 50% (placebo). However, the difference
between the two studies could be explained on the basis of patient selection, as 34% patients in this
study had ascites and 38% had encephalopathy and on the smaller sample size (n= 48). Also less than
half the patients in this study had cirrhosis due to alcohol. Further studies have reported mixed results.
Villeneuve published his negative study in 198611. 79 patients were randomized into a propranolol and
placebo group within 72 hours of bleeding. Out of these, 57 patients had alcoholic cirrhosis. No
difference in the rebleeding rate or survival was observed over a two year period. This study was
criticized for its early randomization of patients as there was a high incidence of early recurrent
hemorrhage and there is evidence that propranolol may not effect portal pressure in the first ten days
following variceal bleeding12. Nevertheless, even when patients who had rebled within the first ten
days were excluded, there was no significant difference in rebleeding at one year. The same was
concluded in the study by Queuniet13 of 99 cirrhotics. 92 of these patients had alcoholic cirrhosis, with
about half being in Child’s A category and this trial therefore disproved the suggestion from earlier
studies that propranolol was only effective in welt compensated cirrhotics. However, some positive
studies have also been reported. In the study by Colombo of94 patients14, there was a significant
reduction in rebleeding with propranolol compared to placebo - 47% vs 25%. Survival was not
improved, but the number of deaths was small. A more recent study is reported by Garden15 who found
a significant lower incidence of rebleeding in modified Child’s C patients receiving propranolol (39%)
than those on placebo (90%). The effect on mortality however, was not significant. The picture
regarding the use of propranolol in secondary prevention therefore, remains confused. A recent meta-
analysis comprising most of the trials of propranolol for prevention of rebleeding from varices shows
that the risk of rebleeding is significantly reduced16, although there was great variability in the
magnitude of benefit. Villeneuve11 concludes that propranolol appears to prevent rebleeding in about
one-third of patients destined to rebleed, but does not improve survival.
Propranolol for primary prevention of variceal hemorrhag
Approximately one third of cirrhotics with esophageal varices bleed and the average mortality due to
the first variceal bleed is around 50%17. Thus primary prevention may offer the best opportunity to
improve prognosis. Recent studies therefore; seem to have concentrated on this aspect and five of these
have been published. Pascalet al reported the first and the largest study in 198717. 230 cirrhotic patients
(90% with alcoholism and 46% with Child’s grade C classification) with large esophageal varices
without previous bleeding were randomly assigned to the propranolol or placebo group, after they had
been divided into two groups according to the severity of their liver disease. On a cumulative analysis,
significantly higher number of patients were free of bleeding at two years in the propranolol group
(74%) compared to the placebo group (39%). Cumulative two year survival was also significantly
improved in the propranolol group (72% vs 51%). Patients with Child’s category C did better than
those with Child’s categoryA. The second largest study is the Italian Multicenter Project for
propranolol in prevention of variceal bleeding19. 174 patients with large varices were randomized to
propranolol or placebo (Vit. K). Less than half had alcoholic cirrhosis while 59% were Child’s class A.
Overall there was no significant difference between the two groups in the number of patients free of
bleeding at one year or in survival at one year. However, if patients in Child’s class A or those without
ascites were analyzed separately, the percentage of patients free of bleeding in the propranolol group
was significantly higher. No difference in survival was seen in any of the subgroups. The conclusion of
the study was that propranolol could prevent first bleeding in patients with well compensated cirrhosis.
Two trials have studied nadolol instead of propranolol for primary prevention of variceal bleeding.
Nadolol was chosen since it is non-cardioselective, is not extensively metabolized in the liver, does not
interfere with renal bleed flow and has been shown to greatly reduce portal pressure20. The larger series
was reported by Lebrec21 of 106 patients, majority of whom had Pugh’s grade A or B disease. The
difference in the percentage of patients free of bleeding and in survival at one year becomes significant
only if "non-complaint" patients were excluded. The smaller of the two trials is by Ideo et al22. 79
patients were studied, approximately half with alcoholic cirrhosis and nearly 75% patients had Child’s
A or B disease. Patients with resistant ascites were excluded. After two years of follow-up, there was a
significant difference in bleeding rates between the treatment and placebo groups, but survival was
unchanged. The latest study is reported by Groszman et al23 of 102 cirrhotics in whom hepatic
hemodynamics were measured before and after the administration of propranolol or placebo. Only 6%
of patients were in the Child’s C category. There was a significant difference in the occurrence of
variceal hemorrhage in the two groups (11 placebo, 2 propranolol treated). All patients who bled had a
hepatic venous pressure gradient (HVPG) of >12 mmHg and no bleeding occurred in patients whose
HVPG decreased to _ 12 mmHg. This agreed with previous studies showing that patients with HVPG
of <12 mmHg were at no risk of bleeding24, therefore, suggesting that this may be the aim of
pharmacologic therapy for PHT. Thus these five trials show that treatment with fl-blocker is safe and
beneficial in cirrhotic patients with large varices who have not previously bled.
Safety of B-blocker therapy in PHT
No fatal complications are reported due to propranolol treatment in cirrhotic patients25. A controlled
study of the safety of propranolol in chronic liver disease by Hayes26 showed that the drug was safe for
long term treatment. Hepatic encephalopathy may worsen if this is already present before B-blocker
therapy is started27. Withdrawal due to patient intolerance is not a great problem, the study by Pascal18
giving an incidence of 17%.
Practical problems in the use of B-blockers for portal hypertension
There are a number of practical problems related to the use of propranolol therapy in portal
hypertension which have to be looked at before solid recommendations about their use can be made.
1. VarIability of response:
It seems clear from various studies that some but not all cirrhotics respond beneficially to propranolol.
As discussed, propranolol reduces portal pressure2,3, probably by a combination of effects3,4. However
it has been shown that only about 30% of cirrhotics with varices who have not bled previously show a
reduction of 20% or more in the basal portal pressure following administration of propranolol28. Even
studies which found that propranolol always reduces the HVPG6,8 showed that the extent of response
was very variable. The reason for this lack of response or its variability is not clear and does not seem
to be predictable on clinical grounds alone. Various explanations have been advanced but none seems
to be confirmed from these studies. For example it has been suggested that higher the pretreatment
portal pressure the greater the response to propranolol2, but this was not confirmed in the study by
Groszmann23. Based on the earlier studies of propranolol in cirrhotics9,2. it was suggested that
propranolol was more effective in Child’s A or B category patients whereas little or less marked
reduction in JJVPG was observed in decompensated cirrhotics7. However, in 2 studies since then, the
severity of liver disease11,13 did not influence the effect of propranolol. The study by Garden15 even
suggested a reduced incidence of rebleeding in patients in Child’s C less treated with propranolol.
Similarly Pascal et al18 demonstrated significant beneficial effects of propranolol on survival in
patients in poor condition but not in those in good condition. Nevertheless, patients with more severe
disease rebleed more irrespective of treatment (propranolol or placebo). Lebrec et al3 found that about
75% of cirrhotics who had survived an episode of variceal hemorrhage exhibited a significant lowering
in portal pressure.
However, the study by Rector2 suggested that a history of previous variceal bleed did not predict the
response to propranolol. The Italian multicentre study19 suggested that cirrhotic patients with resistant
ascites do not respond to beta blockers and may indeed do badly. The reduced density of B-2 receptors
(down- regulation) in these patients has been suggested as the reason why propranolol may not be
effective29. Continued alcohol abuse may effect the therapeutic response to propranolol30.
2. Lack of clinical parameters to determine effectiveness:
If variability of response is a problem, things would be easier if there was an easily measurable end-
point to determine whether propranolol was being effective or not so that a decision about long term
therapy could be rationally made. However, no such correlate exists. Earlier studies8,9 took a 25%
reduction in heart rate as a measure of the effectiveness of propranolol. This however, does not seem to
hold true as in the subsequent negative studies10,11, patients bled despite a lowering in heart rate by
approximately 25%. The study by Rector2 found no correlation between the fall in pulse rate, systolic
blood pressure and portal pressure in response to propranolol. Another study28 found that the percent-
age reduction in heart rate correlated only with the plasma propranolol concentration and not with the
reduction in hepatic venous pressure gradient Groszmann23 suggested that heart rate was useful in
monitoring patient compliance and the potential toxicity of propranolol therapy but provided no further
information. The only reliable indicator of the therapeutic response seems to be a reduction in }WPG of
<12 mmHg. Studies23,24 have clearly shown that patients with HVPG of <12 mmHg were at no risk of
bleeding and in addition there seemed to be a higher cumulative rate of survival. However, there were
no baseline clinical parameters that would identify the patients who would have a reduction in HVPG
to less than 12 mmHg during the course of treatment, except to measure the HVPG at different
intervals23. As mentioned above, several studies have clearly shown that any cirrhotic patient with
varices who has an IIVPG of> 12 mmHg must be at high risk of bleeding. Can such patients be
identified on clinical ground alone without resorting to portal hemodynamic studies? It has been shown
that variceal size is an independent predictive factor for first bleeding31 and that the first episode of
bleeding usually occurs within the first year of diagnosis of varices. In cirrhotic patients whose variceal
size was repeatedly evaluated, variceal bleeding occurred only in those with the largest varices. The
bleeding risk is greater than 40% in patients with large varices according to Beppu et al32. Cales et al33
have recently studied the incidence of bleeding in large esophageal varices with reference to
application of prophylaxis for first bleeding. 84 cirrhotics were entered into the study, 41 of whom had
no varices (grade 0) and 43 had grade one varices. At the end of two years, 31% of those with grade 0
varices at entry and 71% of these with grade one, had developed large varices. The initial Child’s score
had no predictive value for the occurrence of large esophageal varices. Based on these results they
suggest that an upper gastrointestinal endoscopy should be performed every other year in patients with
no varices and every year in patients with grade one varices. This schedule could be simplified further
if prophylaxis is started from the diagnosis of grade zero varices, considering that 70% of such patients
will have grade 2 varices two years later.
CONCLUSION 
Results of trials of primary prophylaxis for variceal bleeding with beta blocker treatment are more
encouraging than the secondary prevention trials. Primary prophylaxis can be recommended for
patients who have large varices at presentation or in whom the variceal size is increasing, except for
patients with gross ascites. Further large studies are needed, particularly from our part of the world,
before propranolol becomes established therapy for primary prophylaxis for variceal bleeding in
patients with cirrhosis.
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